Bangkok Genomics Innovation PCL 

Bangkok Genomics Innovation Public Company Limited, trading as BKGI.BK, is a Thailand-based enterprise delivering a diverse array of clinical and genomic services. Their core genetic offerings include the NIFTY brand for non-invasive prenatal testing, screening for fetal chromosomal abnormalities, and the VISTA brand, which provides genetic disease carrier screening for applications such as pre-embryo implantation, general carrier status, and the detection of gene anomalies linked to thalassemia anemia. Additionally, they offer HPV DNA testing, colon cancer screening under the COLOTECH brand, and personalized genetic analyses through the DNALL brand. Beyond genetic diagnostics, the company provides comprehensive testing for infectious diseases, including real-time PCR, antigen, serology, and neutralizing antibody assays for COVID-19, alongside real-time PCR testing for the monkeypox virus. Their technology solutions segment covers advanced services like DNA and RNA base sequencing, as well as metabolism and protein omics tests. The company also acts as a distributor for essential medical supplies, such as PCR COVID-19 test kits, personal protective equipment (PPE), and vital transport media. BKGI's broader service portfolio encompasses health analytics, medical care, and the development of biotechnology products. They also offer cell advanced therapy medicinal products and provide consulting services for small businesses. Furthermore, the company operates an education center, engages in research activities, and is involved in the retail sale of pharmaceutical products. Remarkably, their operations extend into other sectors, including the provision of heavy machinery such like hydraulic excavators, tractors, wheel-loaded air compressors, and their spare parts, in addition to real estate development. Founded in 2017, Bangkok Genomics Innovation Public Company Limited is headquartered in Bangkok, Thailand.